Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Esophageal Neoplasms × atezolizumab × Clear all

Phase

Status

Sponsor Class

INDUSTRY 6 OTHER 3 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Small Cell Lung Carcinoma 1 Sezary Syndrome 1 Ovarian Neoplasms 1 Mycosis Fungoides 1 Lymphoma, T-Cell, Cutaneous 1 Esophageal Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

Paclitaxel 9 Fluorouracil 9 Cisplatin 9 Radiotherapy 8 Oxaliplatin 6 Irinotecan 5 Leucovorin 4 Docetaxel 4 Cetuximab 4 Carboplatin 3 Taxes 2 Surgical Procedures, Operative 2 Polymerase Chain Reaction 2 Filgrastim 2 Capecitabine 2 uridine triacetate 1 pegylated granulocyte colony-stimulating factor, human 1 pegfilgrastim 1 durvalumab 1 carfilzomib 1 atezolizumab 1 Vorinostat 1 Sorafenib 1 Radiosurgery 1 Psychiatric Rehabilitation 1 Preoperative Exercise 1 Platinum 1 Lithium 1 Granulocyte Colony-Stimulating Factor 1 Gene Expression Profiling 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03818997 2020-02-05

DYNAMIC

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡